|
RedPath Integrated Pathology’s PathFinderTG:
Leading edge, molecular-based cancer diagnostic
testing:
• Combines advances in molecular
genetics with current pathology practices
for an integrated approach
• Provides objective, accurate and
comprehensive analysis
• Leverages advances in imaging and
sampling techniques by working with the
most minute tissue, cytology and fluid samples
• Facilitates personalized medicine
where the unique DNA fingerprint of a tumor allows
for early and definitive diagnosis and individualized
patient care
Clinically Validated
Because PathFinderTG has been clinically
validated and peer-reviewed, you can have
confidence in its quality, accuracy, and
individualized results.
- 95% accuracy rate across validated clinical applications
- 17 years in development and clinical
use
- 15,000+ clinical specimens analyzed
- 129+ peer reviewed medical journal publications
Easy to use
- Complements traditional pathology
practice by integrating morphology with
molecular analysis
- Results are available within 5 business days
- No special collection procedures
- Standard histology slides of fixed, embedded
tissues
- Stained cytology slides, even those with
few cells
- Fine needle aspirates (FNAs)
- Body fluids, effusions, ascites and cyst
aspirates
- Archived, fixed and/or frozen specimens
- RedPath only bills hospitals when required by law
- RedPath never bills physicians unless requested by the physician
- Final report is clear and easy to
understand
The PathFinderTG report is a comprehensive
description that incorporates the morphologic
review with the molecular analysis in a
form that is easily understood and meets CAP guidelines. A written
summary of the number and type of mutations
found, if any, is provided and the temporal
sequence of mutation acquisition is described.
A diagnosis with detailed commentary including
a summary of the molecular profile of the
patient’s specimen is provided in
the context of available clinical history
and pathology information. The report is
delivered via fax.
|
